For Immediate Release March 19, 2003 Media Contact: Bo Piela 617-252-7785 Investor Contact: Sally Curley 617-591-7140 CAMBRIDGE, Mass...
Author: Genzyme
Archive
March 18, 2003
Genzyme continues to make good progress within its program to develop a treatment for Pompe disease. Since our...
Author: Genzyme
Archive
February 17, 2003
Genzyme’s Pompe Program Update Q&A, December 2002 This Question and Answer session is derived from December’s IPA/Genzyme teleconference...
Author: Genzyme
Archive
December 16, 2002
Baarn, October 2nd 2002 Dear IPA members, Herewith I would like to inform you about the IPA/Genzyme telephone...
Author: IPA
Archive
September 23, 2002
On 16/17 April, 2002 Board members of the IPA, the International Pompe Association, met with key representatives of...
Author: IPA/Genzyme
Archive
April 16, 2002
CAMBRIDGE, Mass. and LEIDEN, the Netherlands-Genzyme Corp. and Pharming Group N.V. (Euronext: PHAR / Nasdaq Europe: PHAR) announced...
Author: Genzyme
Archive
December 9, 2001
CAMBRIDGE, Mass.-Genzyme Corp. announced today that it has acquired certain assets of Pharming N.V., the Belgian subsidiary of...
Author: Genzyme
Archive
October 29, 2001
Genzyme quarterly report shows $17.2 million set aside to ensure continued supply of transgenic alpha glucosidase. [NB- this...
Author: Genzyme
Archive
October 17, 2001
Genzyme Completes Acquisition of Novazyme Pharmaceuticals Genzyme Corp. announced September 27 that it has completed the acquisition of...
Author: Genzyme
Archive
September 26, 2001
CAMBRIDGE, Mass. — Genzyme Corporation announced today that it has signed a conditional agreement to acquire certain assets...
Author: Genzyme
Archive
September 18, 2001
1 35 36 37 38